Ifosfamide for injection

This product has no anti-cancer activity in vitro. Once it enters the body, it is hydrolyzed by phosphatase or phosphatase in the liver or tumor, and becomes activated phosphoramide nitrogen mustard to take effect. Its mechanism of action is to cross-link with DNA, inhibit DNA synthesis, and interfere with RNA function. It is a non-specific drug for the cell cycle. This product has a broad anti-tumor spectrum and has inhibitory effects on a variety of tumors.

The main ingredient of this product is ifosfamide.

This product is white crystal or crystalline powder.

Suitable for testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer, etc.

Single drug treatment: 1.2-2.5 g/m2 of body surface area per intravenous injection, 5 consecutive days as a course of treatment. Combination drug treatment: 1.2-2.0 g/m2 of body surface area per intravenous injection, 5 consecutive days as a course of treatment. There is a 3-4 week interval between each course of treatment. 500-600 mg/m2.

(1) Bone marrow suppression: Leukopenia is more common than thrombocytopenia, with the lowest value occurring 1 to 2 weeks after medication, and usually recovering after 2 to 3 weeks. It has an impact on liver function. Gastrointestinal reactions: including loss of appetite, nausea and vomiting, which generally disappear within 1 to 3 days after discontinuation of medication. (2) Urinary tract reactions: can cause hemorrhagic cystitis, manifested as dysuria, frequent urination and dysuria, which may occur within hours or weeks after medication, and usually disappear within a few days after discontinuation of medication. (3) Central nervous system toxicity: related to dose, usually manifested as anxiety, confusion, hallucinations and fatigue. Syncope, epileptic seizures and even coma are rare. (4) Rarely, there is transient asymptomatic liver and kidney function abnormalities; if high doses are used, metabolic acidosis may occur due to renal toxicity. Cardiac and pulmonary toxicity is rare. (5) Other reactions include hair loss, nausea and vomiting. Phlebitis may occur at the injection site. (6) Long-term use of the drug may cause immunosuppression, hypopituitarism, infertility and secondary tumors.

It is contraindicated for patients with severe bone marrow suppression, those who are allergic to this product, and pregnant and lactating women.

Precautions for children: Determine the dosage based on body weight or body surface area, and refer to the above usage and dosage. Precautions for pregnancy and lactation: Prevent use by pregnant and lactating women. Precautions for the elderly: Determine the dosage based on body weight or body surface area, and refer to the above usage and dosage.

1) Patients who have previously received cisplatin may experience increased bone marrow suppression, neurotoxicity, and nephrotoxicity from ifosfamide. (2) Concurrent use of anticoagulants may result in bleeding risk. (3) Concurrent use of hypoglycemic drugs may enhance the hypoglycemic effect. (4) When used in combination with other cytotoxic drugs, the dose should be reduced as appropriate.

Keep in a dark place and sealed at a temperature below 30℃.

1 gram

60 months